TAARGain. Innovative medicines
for brain treatment.

A project by the team of Raul Gainetdinov, an internationally recognized pioneer in amine receptor research. The project is aimed at the development of drugs that use the effects of trace TAAR amines on brain receptors.
The discovery in 2001 of a new class of monoaminergic receptors associated with trace amines opened a new chapter in the development of innovative drugs that radically change human life. Through the efforts of our team of professionals, we carry out a search for pharmaceutical agents for the treatment of a wide range of socially significant human pathologies
Key events in the history of research and development in the field of TAAR.
The pharmaceutical giants could do without us, but they need leads in the form of preliminary data from basic research on receptors; except us, scientists, no one will get this data.
Raul Gainetdinov
Scientific director of the TAARGain project
Trace amines
Trace amines are endogenous amines that are present in vertebrate tissues or fluids at concentrations up to 100 ng/g tissue and selectively bind to one or more TAARs at these concentrations. The first trace amines described, B-phenylethylamine, tyramine, tryptamine, and p-octopamine (classical trace amines), show molecular similarities to the known monoamine neurotransmitters dopamine, epinephrine, norepinephrine, and serotonin. In addition to classical trace amines, their derivatives are described, as well as diamines and polyamines, which are found in the body of mammals, but their functions are not completely clear. Trace amines also enter the human body with food and are synthesized by the symbiotic intestinal microbiota. It is important to note that the content of trace amines in human tissues and model animals changes in some pathologies (schizophrenia, ADHD, ulcerative colitis, epilepsy, etc.), which undoubtedly deserves close attention from the point of view of new targets for psychopharmacology in these diseases.
Attention Deficit Hyperactivity Disorder
Bipolar disorder
Stress-related disorders
Publication in Psychiatric Times

New approaches in the treatment of schizophrenia.

Despite the fact that schizophrenia is universally included in the TOP 15 causes of disability, methods of its treatment have changed little since the 50s.
+7 921 411 84 24
Sredniy prospect
Vasilievsky Island, 88
Saint Petersburg,